Bulletin from the Extraordinary General Meeting of Hansa Medical AB (publ)
“The new name Hansa Biopharma emphasizes our focus on the development and commercialization of biological drugs, biopharmaceuticals. This refinement of our profile is particularly important for the continued internationalization of our business and our investor base.” said Søren Tulstrup, President and CEO of Hansa Medical.
Today, the Company has further submitted the resolution and the new company name for registration to the Swedish Companies Registration Office. The launch of the Company’s new name, including updated web page and graphical profile, is expected to take place on or about the beginning of 2019.
The information was submitted for publication, through the agency of the contact persons set out below, on December 11, 2018 at 1:00pm CET.
For further information, please contact:
Emanuel Björne, Vice President Business Development and Investor Relations, Hansa Medical AB (publ)
Mobile: +46 707 175477
Swedish Investor and Media Relations:
+46 70-311 99 60
U.K. Investor and Media Relations
Simon Conway/ Stephanie Cuthbert
+44 (0)20 3727 1000
U.S. Investor and Media Relations:
Stephanie Marks/ David Rosen (media)
+1 212 600 1902